20 research outputs found
Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase) : novel global treatment response model and outcomes in patients with alpha-mannosidosis
Alpha-mannosidosis is an ultra-rare monogenic disorder resulting from a deficiency in the lysosomal enzyme
alpha-mannosidase, with a prevalence estimated to be as low as 1:1,000,000 live births. The resulting accumulation
of mannose-rich oligosaccharides in all tissues leads to a very heterogeneous disorder with a continuum
of clinical manifestations with no distinctive phenotypes. Long-term enzyme replacement therapy (ERT) with
velmanase alfa is approved in Europe for the treatment of non-neurological manifestations in patients with mild
to moderate alpha-mannosidosis. The clinical heterogeneity and rarity of the disease limit the sensitivity of
single parameters to detect clinically relevant treatment effects. Thus, we propose a novel multiple variable
responder analysis to evaluate the efficacy of ERT for alpha-mannosidosis and present efficacy analyses for
velmanase alfa using this method.
Global treatment response to velmanase alfa (defined by response to ≥2 domains comprising pharmacodynamic,
functional, and quality of life outcomes) was applied post hoc to data from the pivotal placebo-controlled
rhLAMAN-05 study and to the longer-term integrated data from all patients in the clinical development program
(rhLAMAN-10). After 12 months of treatment, a global treatment response was achieved by 87% of patients
receiving velmanase alfa (n=15) compared with 30% of patients receiving placebo (n=10). Longer-term data
from all patients in the clinical program (n=33) showed 88% of patients were global responders, including all
(100%) pediatric patients (n=19) and the majority (71%) of adult patients (n=14). The responder analysis
model demonstrates a clinically meaningful treatment effect with velmanase alfa and supports the early initiation
and continued benefit of longer-term treatment of all patients with alpha-mannosidosis with this ERT.Phase I/II studies rhLAMAN-02, -03, and -04 and phase III study
rhLAMAN-05 were conducted under and co-funded by the EU FP7
project ALPHA-MAN [FP7-HEALTH-2010-261331]. Long-term continuation studies rhLAMAN-07 and -09 were initially sponsored by
Zymenex A/S and are currently sponsored by Chiesi Farmaceutici S.p.A.
Zymenex sponsored rhLAMAN-10.
Chiesi Farmaceutici S.p.A. funded third-party writing assistance for
the current manuscript, provided by PAREXEL.https://www.elsevier.com/locate/ymgmeam2019Paediatrics and Child Healt
SONDEO ARQUEOLÓGICO SECTOR 84 [Material gráfico]
Copia digital. Madrid : Ministerio de EducaciĂłn, Cultura y Deporte, 201
Concomitant familial hypocalciuric hypercalcemia and single parathyroid adenoma:a case report
BACKGROUND: Primary hyperparathyroidism (PHPT) is a common endocrine disorder and the most frequent benign cause of hypercalcemia. PHPT is characterized by autonomous hypersecretion of parathyroid hormone (PTH), regardless of serum calcium levels. Familial hypocalciuric hypercalcemia (FHH) is a rare, benign syndrome only affecting the regulation of calcium metabolism. FHH is an autosomal-dominant genetic disease with high penetrance, caused by an inactivating variant in the CASR gene encoding the calcium-sensing receptor (CaSR). We present a unique case of concomitant PHPT and FHH without clinically actionable variants in MEN1. CASE PRESENTATION: A 47-year-old Caucasian man with severe hypercalcemia, genetic FHH, and initially normal parathyroid scintigraphy was referred for endocrine evaluation due to nonspecific symptoms. Biochemical evaluation showed elevated serum ionized calcium and PTH. The calcium–creatinine clearance ratio was low. All other biochemical measures were normal, including kidney function. Genetic evaluation was redone and confirmed FHH. A new parathyroid scintigraphy showed a significant single adenoma corresponding to the lower left gland. The patient underwent parathyroidectomy, and a parathyroid adenoma was removed. A reduced level of hypercalcemia persisted due to FHH. CONCLUSIONS: The correct diagnosis of the underlying cause of hypercalcemia is important to ensure the right treatment. Patients with FHH should avoid operative treatment, and PHPT should be differentiated from MEN1 to determine whether surgery should include parathyroidectomy with removal of one adenoma or 3.5 hyperplastic parathyroid glands